nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—Glomerulonephritis—Propylthiouracil—Graves' disease	0.0827	0.158	CcSEcCtD
Tacrolimus—ABCA5—eye—Graves' disease	0.0356	0.106	CbGeAlD
Tacrolimus—Lung infiltration—Propylthiouracil—Graves' disease	0.0322	0.0617	CcSEcCtD
Tacrolimus—ABCA5—pituitary gland—Graves' disease	0.0264	0.0786	CbGeAlD
Tacrolimus—ABCA5—adipose tissue—Graves' disease	0.0263	0.0783	CbGeAlD
Tacrolimus—PPP3CA—connective tissue—Graves' disease	0.0231	0.0689	CbGeAlD
Tacrolimus—ABCA5—thyroid gland—Graves' disease	0.0227	0.0678	CbGeAlD
Tacrolimus—Interstitial lung disease—Propylthiouracil—Graves' disease	0.0213	0.0409	CcSEcCtD
Tacrolimus—Skin ulcer—Propylthiouracil—Graves' disease	0.0194	0.0372	CcSEcCtD
Tacrolimus—Liver injury—Propylthiouracil—Graves' disease	0.018	0.0344	CcSEcCtD
Tacrolimus—PPP3CA—pituitary gland—Graves' disease	0.0178	0.0531	CbGeAlD
Tacrolimus—PPP3CA—adipose tissue—Graves' disease	0.0178	0.0529	CbGeAlD
Tacrolimus—MTOR—eye—Graves' disease	0.0177	0.0529	CbGeAlD
Tacrolimus—MTOR—connective tissue—Graves' disease	0.0171	0.0509	CbGeAlD
Tacrolimus—FKBP1A—eye—Graves' disease	0.016	0.0475	CbGeAlD
Tacrolimus—FKBP1A—connective tissue—Graves' disease	0.0154	0.0458	CbGeAlD
Tacrolimus—PPP3CA—thyroid gland—Graves' disease	0.0154	0.0458	CbGeAlD
Tacrolimus—Lymphadenopathy—Methimazole—Graves' disease	0.0151	0.029	CcSEcCtD
Tacrolimus—MTOR—pituitary gland—Graves' disease	0.0132	0.0392	CbGeAlD
Tacrolimus—MTOR—adipose tissue—Graves' disease	0.0131	0.0391	CbGeAlD
Tacrolimus—Lymphadenopathy—Propylthiouracil—Graves' disease	0.0129	0.0246	CcSEcCtD
Tacrolimus—Hepatic failure—Propylthiouracil—Graves' disease	0.0122	0.0234	CcSEcCtD
Tacrolimus—Renal failure acute—Propylthiouracil—Graves' disease	0.0119	0.0228	CcSEcCtD
Tacrolimus—FKBP1A—pituitary gland—Graves' disease	0.0118	0.0353	CbGeAlD
Tacrolimus—FKBP1A—adipose tissue—Graves' disease	0.0118	0.0351	CbGeAlD
Tacrolimus—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.0116	0.0223	CcSEcCtD
Tacrolimus—MTOR—thyroid gland—Graves' disease	0.0114	0.0338	CbGeAlD
Tacrolimus—FKBP1A—thyroid gland—Graves' disease	0.0102	0.0304	CbGeAlD
Tacrolimus—Neuropathy peripheral—Methimazole—Graves' disease	0.00974	0.0187	CcSEcCtD
Tacrolimus—Jaundice—Methimazole—Graves' disease	0.00969	0.0186	CcSEcCtD
Tacrolimus—Agranulocytosis—Methimazole—Graves' disease	0.00928	0.0178	CcSEcCtD
Tacrolimus—Hepatitis—Methimazole—Graves' disease	0.00892	0.0171	CcSEcCtD
Tacrolimus—PPP3CA—T-Cell Receptor and Co-stimulatory Signaling—CTLA4—Graves' disease	0.00866	0.0609	CbGpPWpGaD
Tacrolimus—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00829	0.0159	CcSEcCtD
Tacrolimus—Jaundice—Propylthiouracil—Graves' disease	0.00824	0.0158	CcSEcCtD
Tacrolimus—Agranulocytosis—Propylthiouracil—Graves' disease	0.00789	0.0151	CcSEcCtD
Tacrolimus—Alopecia—Methimazole—Graves' disease	0.00789	0.0151	CcSEcCtD
Tacrolimus—Haemoglobin—Propylthiouracil—Graves' disease	0.00763	0.0146	CcSEcCtD
Tacrolimus—Haemorrhage—Propylthiouracil—Graves' disease	0.00759	0.0145	CcSEcCtD
Tacrolimus—Hepatitis—Propylthiouracil—Graves' disease	0.00759	0.0145	CcSEcCtD
Tacrolimus—Vertigo—Methimazole—Graves' disease	0.00698	0.0134	CcSEcCtD
Tacrolimus—Leukopenia—Methimazole—Graves' disease	0.00695	0.0133	CcSEcCtD
Tacrolimus—Alopecia—Propylthiouracil—Graves' disease	0.00671	0.0128	CcSEcCtD
Tacrolimus—PPP3CA—T-Cell Receptor and Co-stimulatory Signaling—CD8A—Graves' disease	0.00666	0.0469	CbGpPWpGaD
Tacrolimus—Myalgia—Methimazole—Graves' disease	0.00661	0.0127	CcSEcCtD
Tacrolimus—Arthralgia—Methimazole—Graves' disease	0.00661	0.0127	CcSEcCtD
Tacrolimus—Dysgeusia—Propylthiouracil—Graves' disease	0.00647	0.0124	CcSEcCtD
Tacrolimus—Oedema—Methimazole—Graves' disease	0.00634	0.0121	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methimazole—Graves' disease	0.00621	0.0119	CcSEcCtD
Tacrolimus—Vertigo—Propylthiouracil—Graves' disease	0.00593	0.0114	CcSEcCtD
Tacrolimus—Leukopenia—Propylthiouracil—Graves' disease	0.00591	0.0113	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00578	0.0111	CcSEcCtD
Tacrolimus—Paraesthesia—Methimazole—Graves' disease	0.00569	0.0109	CcSEcCtD
Tacrolimus—Somnolence—Methimazole—Graves' disease	0.00564	0.0108	CcSEcCtD
Tacrolimus—Myalgia—Propylthiouracil—Graves' disease	0.00562	0.0108	CcSEcCtD
Tacrolimus—Arthralgia—Propylthiouracil—Graves' disease	0.00562	0.0108	CcSEcCtD
Tacrolimus—Dyspepsia—Methimazole—Graves' disease	0.00558	0.0107	CcSEcCtD
Tacrolimus—Oedema—Propylthiouracil—Graves' disease	0.00539	0.0103	CcSEcCtD
Tacrolimus—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SCGB3A2—Graves' disease	0.00534	0.0375	CbGpPWpGaD
Tacrolimus—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00528	0.0101	CcSEcCtD
Tacrolimus—CYP3A5—adipose tissue—Graves' disease	0.00514	0.0153	CbGeAlD
Tacrolimus—Urticaria—Methimazole—Graves' disease	0.00504	0.00965	CcSEcCtD
Tacrolimus—Body temperature increased—Methimazole—Graves' disease	0.00501	0.0096	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00491	0.00941	CcSEcCtD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—FASLG—Graves' disease	0.00486	0.0342	CbGpPWpGaD
Tacrolimus—Paraesthesia—Propylthiouracil—Graves' disease	0.00484	0.00927	CcSEcCtD
Tacrolimus—Somnolence—Propylthiouracil—Graves' disease	0.00479	0.00918	CcSEcCtD
Tacrolimus—Dyspepsia—Propylthiouracil—Graves' disease	0.00475	0.00909	CcSEcCtD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2RA—Graves' disease	0.00466	0.0328	CbGpPWpGaD
Tacrolimus—Pruritus—Methimazole—Graves' disease	0.00449	0.00859	CcSEcCtD
Tacrolimus—Urticaria—Propylthiouracil—Graves' disease	0.00428	0.0082	CcSEcCtD
Tacrolimus—Body temperature increased—Propylthiouracil—Graves' disease	0.00426	0.00816	CcSEcCtD
Tacrolimus—Vomiting—Methimazole—Graves' disease	0.00403	0.00772	CcSEcCtD
Tacrolimus—Rash—Methimazole—Graves' disease	0.004	0.00766	CcSEcCtD
Tacrolimus—Dermatitis—Methimazole—Graves' disease	0.00399	0.00765	CcSEcCtD
Tacrolimus—Headache—Methimazole—Graves' disease	0.00397	0.00761	CcSEcCtD
Tacrolimus—Pruritus—Propylthiouracil—Graves' disease	0.00381	0.0073	CcSEcCtD
Tacrolimus—Nausea—Methimazole—Graves' disease	0.00377	0.00721	CcSEcCtD
Tacrolimus—Vomiting—Propylthiouracil—Graves' disease	0.00343	0.00656	CcSEcCtD
Tacrolimus—Rash—Propylthiouracil—Graves' disease	0.0034	0.00651	CcSEcCtD
Tacrolimus—Dermatitis—Propylthiouracil—Graves' disease	0.0034	0.0065	CcSEcCtD
Tacrolimus—Headache—Propylthiouracil—Graves' disease	0.00338	0.00647	CcSEcCtD
Tacrolimus—Nausea—Propylthiouracil—Graves' disease	0.0032	0.00613	CcSEcCtD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—Graves' disease	0.00307	0.0216	CbGpPWpGaD
Tacrolimus—MTOR—CXCR3-mediated signaling events—CXCL10—Graves' disease	0.00276	0.0194	CbGpPWpGaD
Tacrolimus—MTOR—TSH signaling pathway—TSHR—Graves' disease	0.00275	0.0193	CbGpPWpGaD
Tacrolimus—ABCB1—pituitary gland—Graves' disease	0.00274	0.00816	CbGeAlD
Tacrolimus—ABCB1—adipose tissue—Graves' disease	0.00273	0.00813	CbGeAlD
Tacrolimus—PPP3CA—Alzheimers Disease—FAS—Graves' disease	0.00271	0.0191	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—CXCL10—Graves' disease	0.00256	0.018	CbGpPWpGaD
Tacrolimus—ABCB1—thyroid gland—Graves' disease	0.00236	0.00704	CbGeAlD
Tacrolimus—MTOR—IL2 signaling events mediated by PI3K—IL2RA—Graves' disease	0.00216	0.0152	CbGpPWpGaD
Tacrolimus—PPP3CA—Amyotrophic lateral sclerosis (ALS)—TNF—Graves' disease	0.00207	0.0145	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—CXCL10—Graves' disease	0.00198	0.0139	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—CTLA4—Graves' disease	0.00191	0.0134	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—Graves' disease	0.00187	0.0131	CbGpPWpGaD
Tacrolimus—MTOR—TSLP Signaling Pathway—IL2RA—Graves' disease	0.00178	0.0125	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—ICAM1—Graves' disease	0.00169	0.0119	CbGpPWpGaD
Tacrolimus—PPP3CA—C-MYB transcription factor network—CD4—Graves' disease	0.00163	0.0115	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—CD8A—Graves' disease	0.00162	0.0114	CbGpPWpGaD
Tacrolimus—PPP3CA—Alzheimers Disease—IL1B—Graves' disease	0.00159	0.0111	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—HLA-DQB1—Graves' disease	0.00157	0.0111	CbGpPWpGaD
Tacrolimus—PPP3CA—Cardiac Hypertrophic Response—TNF—Graves' disease	0.00154	0.0108	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—FASLG—Graves' disease	0.00154	0.0108	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—FASLG—Graves' disease	0.00153	0.0107	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—FAS—Graves' disease	0.00148	0.0104	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—IL2RA—Graves' disease	0.00146	0.0103	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—HLA-A—Graves' disease	0.00145	0.0102	CbGpPWpGaD
Tacrolimus—MTOR—Type II diabetes mellitus—TNF—Graves' disease	0.00139	0.00981	CbGpPWpGaD
Tacrolimus—MTOR—RANKL/RANK Signaling Pathway—ICAM1—Graves' disease	0.00136	0.00957	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—HLA-DRB1—Graves' disease	0.00132	0.0093	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—ICAM1—Graves' disease	0.00131	0.00924	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—IFNG—Graves' disease	0.00129	0.00907	CbGpPWpGaD
Tacrolimus—MTOR—IFN-gamma pathway—IFNG—Graves' disease	0.00126	0.00887	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—Graves' disease	0.00121	0.00851	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—HLA-DRB1—Graves' disease	0.0012	0.00842	CbGpPWpGaD
Tacrolimus—PPP3CA—Alzheimers Disease—TNF—Graves' disease	0.00115	0.00809	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—IL1B—Graves' disease	0.00115	0.00809	CbGpPWpGaD
Tacrolimus—MTOR—IFN-gamma pathway—IL1B—Graves' disease	0.00112	0.00791	CbGpPWpGaD
Tacrolimus—PPP3CA—MicroRNAs in cardiomyocyte hypertrophy—TNF—Graves' disease	0.0011	0.0077	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.00108	0.00756	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—IFIH1—Graves' disease	0.00105	0.00735	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.00104	0.00729	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—HLA-DRB1—Graves' disease	0.00101	0.00711	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—IFNG—Graves' disease	0.001	0.00703	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—HLA-E—Graves' disease	0.000981	0.0069	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—IFNG—Graves' disease	0.000966	0.00679	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—CD4—Graves' disease	0.000933	0.00656	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—HLA-E—Graves' disease	0.000923	0.00649	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—IL1B—Graves' disease	0.000892	0.00627	CbGpPWpGaD
Tacrolimus—MTOR—Regulation of Telomerase—IFNG—Graves' disease	0.000874	0.00615	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—IL1B—Graves' disease	0.000867	0.0061	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—IL1B—Graves' disease	0.000862	0.00606	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—CD4—Graves' disease	0.000844	0.00594	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—TNF—Graves' disease	0.000834	0.00587	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—HLA-E—Graves' disease	0.000822	0.00578	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—HLA-E—Graves' disease	0.000757	0.00533	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CD40—Graves' disease	0.00074	0.00521	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CTLA4—Graves' disease	0.00073	0.00513	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—B3GNT2—Graves' disease	0.000721	0.00507	CbGpPWpGaD
Tacrolimus—MTOR—Leptin signaling pathway—IL1B—Graves' disease	0.000721	0.00507	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—CD4—Graves' disease	0.000713	0.00501	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—ICAM1—Graves' disease	0.00071	0.005	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—TSHR—Graves' disease	0.000709	0.00498	CbGpPWpGaD
Tacrolimus—MTOR—Cardiac Hypertrophic Response—TNF—Graves' disease	0.00067	0.00471	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—HLA-B—Graves' disease	0.000658	0.00462	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—TNF—Graves' disease	0.000647	0.00455	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—TNF—Graves' disease	0.000629	0.00442	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—Graves' disease	0.000617	0.00434	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IFIH1—Graves' disease	0.000609	0.00428	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	0.000601	0.00423	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—HLA-B—Graves' disease	0.000586	0.00412	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—ICAM1—Graves' disease	0.000578	0.00406	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—B3GNT2—Graves' disease	0.000559	0.00393	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—Graves' disease	0.000551	0.00387	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—IFNG—Graves' disease	0.00054	0.0038	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—HLA-B—Graves' disease	0.00054	0.0038	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—FASLG—Graves' disease	0.000528	0.00371	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—FAS—Graves' disease	0.000509	0.00358	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL2RA—Graves' disease	0.000506	0.00356	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—HLA-A—Graves' disease	0.0005	0.00352	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—IL1B—Graves' disease	0.000482	0.00339	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-E—Graves' disease	0.000479	0.00337	CbGpPWpGaD
Tacrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—Graves' disease	0.000478	0.00336	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD40—Graves' disease	0.000468	0.00329	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CTLA4—Graves' disease	0.000461	0.00324	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000459	0.00323	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CXCL10—Graves' disease	0.000458	0.00322	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	0.000457	0.00321	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—IFIH1—Graves' disease	0.000456	0.00321	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.00044	0.0031	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IFNG—Graves' disease	0.00044	0.00309	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TSHR—Graves' disease	0.000419	0.00294	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IL1B—Graves' disease	0.000392	0.00276	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000384	0.0027	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-DQB1—Graves' disease	0.00038	0.00267	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HLA-E—Graves' disease	0.000359	0.00252	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD8A—Graves' disease	0.000355	0.00249	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL2RA—Graves' disease	0.00035	0.00246	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—TNF—Graves' disease	0.00035	0.00246	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CD4—Graves' disease	0.00035	0.00246	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IFNG—Graves' disease	0.000349	0.00246	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-E—Graves' disease	0.000344	0.00242	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-B—Graves' disease	0.000341	0.0024	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000339	0.00238	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD40—Graves' disease	0.000337	0.00237	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IFNG—Graves' disease	0.000334	0.00235	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CTLA4—Graves' disease	0.000332	0.00233	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TSHR—Graves' disease	0.000325	0.00228	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL2RA—Graves' disease	0.00032	0.00225	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-A—Graves' disease	0.000316	0.00222	CbGpPWpGaD
Tacrolimus—MTOR—Disease—B3GNT2—Graves' disease	0.000315	0.00221	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IL1B—Graves' disease	0.000312	0.00219	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL1B—Graves' disease	0.000298	0.00209	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000297	0.00209	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HLA-A—Graves' disease	0.000292	0.00205	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-DRB1—Graves' disease	0.000289	0.00203	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TNF—Graves' disease	0.000285	0.002	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—ICAM1—Graves' disease	0.000277	0.00195	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GC—Graves' disease	0.000274	0.00193	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-DQB1—Graves' disease	0.000273	0.00192	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CXCL10—Graves' disease	0.00027	0.0019	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFIH1—Graves' disease	0.000265	0.00187	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.00026	0.00183	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HLA-B—Graves' disease	0.000255	0.0018	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD8A—Graves' disease	0.000255	0.00179	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000253	0.00178	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000251	0.00177	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-B—Graves' disease	0.000245	0.00173	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-A—Graves' disease	0.000227	0.0016	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HLA-A—Graves' disease	0.000226	0.00159	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—TNF—Graves' disease	0.000226	0.00159	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—TNF—Graves' disease	0.000216	0.00152	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IFNG—Graves' disease	0.000211	0.00148	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCL10—Graves' disease	0.00021	0.00148	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-E—Graves' disease	0.000209	0.00147	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—B3GNT2—Graves' disease	0.000208	0.00146	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-DRB1—Graves' disease	0.000208	0.00146	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL2RA—Graves' disease	0.000207	0.00145	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD40—Graves' disease	0.000204	0.00144	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD4—Graves' disease	0.000204	0.00143	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CTLA4—Graves' disease	0.000201	0.00141	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ICAM1—Graves' disease	0.000199	0.0014	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GC—Graves' disease	0.000198	0.00139	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL1B—Graves' disease	0.000188	0.00132	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CD4—Graves' disease	0.000188	0.00132	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TSHR—Graves' disease	0.000183	0.00128	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GC—Graves' disease	0.000171	0.0012	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-DQB1—Graves' disease	0.000166	0.00117	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2RA—Graves' disease	0.00016	0.00113	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD8A—Graves' disease	0.000155	0.00109	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CD4—Graves' disease	0.000153	0.00107	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—B3GNT2—Graves' disease	0.00015	0.00106	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GC—Graves' disease	0.00015	0.00105	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-B—Graves' disease	0.000149	0.00105	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD4—Graves' disease	0.000146	0.00103	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CD4—Graves' disease	0.000146	0.00103	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2RA—Graves' disease	0.000139	0.000981	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-A—Graves' disease	0.000138	0.00097	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2RA—Graves' disease	0.000131	0.000919	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—B3GNT2—Graves' disease	0.000129	0.00091	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HLA-A—Graves' disease	0.000127	0.000895	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-DRB1—Graves' disease	0.000126	0.000886	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ICAM1—Graves' disease	0.000121	0.00085	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL10—Graves' disease	0.000118	0.00083	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—B3GNT2—Graves' disease	0.000113	0.000798	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000107	0.00075	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GC—Graves' disease	9.22e-05	0.000648	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFNG—Graves' disease	9.2e-05	0.000647	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2RA—Graves' disease	9.01e-05	0.000634	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD4—Graves' disease	8.88e-05	0.000625	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL1B—Graves' disease	8.21e-05	0.000577	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD4—Graves' disease	8.2e-05	0.000577	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—B3GNT2—Graves' disease	6.99e-05	0.000491	CbGpPWpGaD
